+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Multiple Sclerosis Market by Multiple Sclerosis Type, Mechanism of Action, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968783
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior leaders across the biopharmaceutical and healthcare ecosystem are confronting a rapidly changing multiple sclerosis market marked by evolving therapies, complex regulatory trends, and intensifying competition. Strategic visibility into this dynamic landscape is critical for informed investment, commercialization, and partnership decisions.

Market Snapshot: Multiple Sclerosis Market Overview

The Multiple Sclerosis Market grew from USD 18.05 billion in 2024 to USD 19.59 billion in 2025. It is expected to continue growing at a CAGR of 8.28%, reaching USD 29.11 billion by 2030.

Market progress is fueled by accelerated therapeutic innovation and greater integration of digital health, as well as evolving payer strategies and regional dynamics. Industry stakeholders are navigating the intersection of clinical needs, regulatory shifts, and rising demand for precision medicine. The resulting environment presents both new competition and novel opportunities for differentiation and long-term growth.

Scope & Segmentation

This report provides comprehensive coverage of the multiple sclerosis market, offering in-depth analysis across the following dimensions:

  • Multiple Sclerosis Types: Primary Progressive, Relapsing Remitting, Secondary Progressive
  • Mechanism of Action: Fumarate therapies, Immunomodulators (Glatiramer Acetate, Interferons), Immunosuppressants (Mitoxantrone), Monoclonal Antibodies (Alemtuzumab, Natalizumab, Ocrelizumab, Ofatumumab), Sphingosine 1 Phosphate Receptor Modulators (Fingolimod, Ozanimod, Ponesimod, Siponimod)
  • Route of Administration: Injectable, Intravenous, Oral
  • Distribution Channels: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
  • End User Environments: Home Care Settings, Hospitals, Specialty Clinics
  • Regional Analysis: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Key Companies Profiled: Biogen Inc., Novartis AG, Roche Holding AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Merck KGaA, Bayer AG, Pfizer Inc., Johnson & Johnson

Key Takeaways

  • Therapeutic innovation is advancing as molecular targeting, digital therapeutics, and real-world evidence become central to drug development and delivery strategies.
  • Precision medicine approaches are being clinically implemented, providing targeted options for specific patient populations based on genetic and progression profiles.
  • Digital health platforms, including telemedicine, are enhancing patient engagement and expanding access beyond traditional settings.
  • Collaboration between large pharmaceutical companies and agile biotech firms is intensifying, driving earlier adoption and broader market coverage of new therapies.
  • Value-based contracting and payer demand for outcome evidence are shifting market access models, affecting pricing, reimbursement, and product differentiation.
  • Regional market differences are pronounced, with developed and emerging markets exhibiting varied adoption trajectories, access barriers, and investment levels.

Tariff Impact on Multiple Sclerosis Market

Forthcoming cumulative United States tariffs scheduled for 2025 are creating cost pressures throughout the supply chain. Manufacturers importing active pharmaceutical ingredients are experiencing higher expenses, leading to increased inventory risks and the need to rethink global sourcing. Organizations are responding with risk mitigation measures such as nearshoring, supplier diversification, and dynamic pricing in contract negotiations. These shifts highlight the need for flexible supply chain management and proactive pricing strategies to offset tariff-driven disruption and protect margins.

Methodology & Data Sources

This analysis utilizes a rigorous combination of primary and secondary research. Peer-reviewed journals, regulatory filings, clinical trial registries, and industry white papers formed the basis for published evidence. Structured interviews with industry experts, payers, clinicians, and patient advocates provided qualitative insights, ensuring a balanced and validated perspective. Quantitative trends were corroborated through statistical and regional analysis for robust strategic guidance.

Why This Report Matters

  • Enables senior decision-makers to benchmark innovation, partnership, and access strategies within an evolving competitive environment.
  • Offers granular segmentation and regional analysis for optimized resource allocation and targeted market entry planning.

Conclusion

This report synthesizes the multidimensional factors shaping the multiple sclerosis market, providing actionable intelligence for leadership teams intent on advancing successful portfolio strategies. Proactive integration of real-world insights and agile commercialization will drive sustainable value and patient benefit.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Multiple Sclerosis Market, by Multiple Sclerosis Type
8.1. Introduction
8.2. Primary Progressive
8.3. Relapsing Remitting
8.4. Secondary Progressive
9. Multiple Sclerosis Market, by Mechanism of Action
9.1. Introduction
9.2. Fumarate Therapies
9.3. Immunomodulators
9.3.1. Glatiramer Acetate
9.3.2. Interferons
9.4. Immunosuppressants
9.4.1. Mitoxantrone
9.5. Monoclonal Antibodies
9.5.1. Alemtuzumab
9.5.2. Natalizumab
9.5.3. Ocrelizumab
9.5.4. Ofatumumab
9.6. Sphingosine 1 Phosphate Receptor Modulators
9.6.1. Fingolimod
9.6.2. Ozanimod
9.6.3. Ponesimod
9.6.4. Siponimod
10. Multiple Sclerosis Market, by Route of Administration
10.1. Introduction
10.2. Injectable
10.3. Intravenous
10.4. Oral
11. Multiple Sclerosis Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Multiple Sclerosis Market, by End User
12.1. Introduction
12.2. Home Care Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Multiple Sclerosis Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Multiple Sclerosis Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Multiple Sclerosis Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Biogen Inc.
16.3.2. Novartis AG
16.3.3. Roche Holding AG
16.3.4. Sanofi S.A.
16.3.5. Teva Pharmaceutical Industries Ltd.
16.3.6. Bristol-Myers Squibb Company
16.3.7. Merck KGaA
16.3.8. Bayer AG
16.3.9. Pfizer Inc.
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MULTIPLE SCLEROSIS MARKET MULTI-CURRENCY
FIGURE 2. MULTIPLE SCLEROSIS MARKET MULTI-LANGUAGE
FIGURE 3. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RELAPSING REMITTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SECONDARY PROGRESSIVE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FUMARATE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GLATIRAMER ACETATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MITOXANTRONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ALEMTUZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY NATALIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OCRELIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OFATUMUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY FINGOLIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY OZANIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY PONESIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SIPONIMOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 63. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 66. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 67. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 68. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 69. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 119. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 120. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 121. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 128. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 130. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 131. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 132. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 146. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 148. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 149. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 150. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 151. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 155. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 156. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 157. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 158. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 159. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 191. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 193. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 194. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 195. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 209. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 210. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 211. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 212. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 213. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 214. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 218. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 219. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 220. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 221. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 222. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 245. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 246. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 247. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 249. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 254. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 255. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 256. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 257. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 258. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 272. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 274. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 275. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 276. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 281. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 282. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 283. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 284. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 285. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 286. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 287. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 289. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 298. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 308. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 309. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 310. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 311. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 312. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 313. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS, 2018-2030 (USD MILLION)
TABLE 314. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 315. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 316. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 317. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MULTIPLE SCLEROSIS TYPE, 2018-2030 (USD MILLION)
TABLE 318. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 319. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOMODULATORS, 2018-2030 (USD MILLION)
TABLE 320. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
TABLE 321. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Multiple Sclerosis market report include:
  • Biogen Inc.
  • Novartis AG
  • Roche Holding AG
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Merck KGaA
  • Bayer AG
  • Pfizer Inc.
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 19.59 Billion
Forecasted Market Value ( USD ) by 2030 $ 29.11 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Multiple Sclerosis Drugs Market Report 2025 - Product Image

Multiple Sclerosis Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Relapsing Remitting Multiple Sclerosis Market - Product Image

Relapsing Remitting Multiple Sclerosis Market

  • Report
  • 250 Pages
  • Global
From
Multiple Sclerosis Therapeutics - Global Strategic Business Report - Product Image

Multiple Sclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 164 Pages
  • Global
From
Multiple Sclerosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type - Product Image

Multiple Sclerosis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

  • Report
  • 97 Pages
  • Global
From
Multiple Sclerosis Treatment Market Report and Forecast 2024-2032 - Product Image

Multiple Sclerosis Treatment Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From

About the Multiple Sclerosis Drug Market

The Multiple Sclerosis (MS) Drug market is a subset of the Central Nervous System (CNS) Drugs market. MS is a chronic, progressive neurological disorder that affects the central nervous system, causing a wide range of physical and mental symptoms. MS drugs are used to reduce the frequency and severity of MS relapses, slow the progression of the disease, and improve the quality of life of those affected. MS drugs are typically divided into two categories: disease-modifying therapies (DMTs) and symptomatic therapies. DMTs are used to slow the progression of the disease, while symptomatic therapies are used to manage the symptoms of MS. Common DMTs include interferon beta, glatiramer acetate, fingolimod, and natalizumab. Common symptomatic therapies include muscle relaxants, antispasmodics, and antidepressants. The MS Drug market is highly competitive, with a number of major pharmaceutical companies competing for market share. Some of the major players in the market include Biogen, Novartis, Merck, Sanofi, and Teva Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.